NEW YORK and BERLIN, Nov. 17, 2022 (GLOBE NEWSWIRE) — atai Life Sciences N.V. (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced it has initiated a clinical study with Massachusetts General Hospital (MGH). The study will utilize a neuroimaging method to identify neuroplasticity biomarkers in patients…


Previous articlePT374 – Personalizing Psychedelic Integration
Next articleNuminus to Participate in a Water Tower Research Fireside Chat on Thursday, December 8, 2022